Axsome Therapeutics to Present at the 2018 BIO International Convention
May 22, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
May 03, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
April 24, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
March 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression
February 14, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
March 17, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
First Patient Enrolled in the STRIDE-1 Study Second Product Candidate Axsome Has Advanced into a Pivotal Trial NEW YORK, March 17, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc....